{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:04:32Z","timestamp":1783677872662,"version":"3.55.0"},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,5,27]],"date-time":"2018-05-27T00:00:00Z","timestamp":1527379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Vet Comparative Oncology"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:p>In dogs, inflammatory mammary carcinoma is a clinicopathological entity characterized by rapid progression and aggressive behavior from onset of disease. Reported median survival time is short, with no effective treatment options. The aims of this prospective, noncontrolled clinical trial were to investigate outcome variables and safety profile of toceranib, thalidomide and piroxicam with or without hypofractionated radiation therapy in dogs with measurable histologically confirmed inflammatory mammary carcinoma that underwent a complete staging. Eighteen dogs were enrolled: 14 received medical treatment, and 4 were treated with hypofractionated radiation therapy and medical therapy. Overall, median time to progression was 34 days and median survival time was 109 days. In dogs treated with medical therapy, overall response rate was 21%, and clinical benefit rate (CBR) was 64%; median time to progression was 28 days and median survival time was 59 days. In dogs receiving medical therapy and undergoing radiation therapy, overall response rate and clinical benefit rate were 100%, with significantly longer time to progression (156 days) and survival time (180 days). Overall, treatment was well tolerated, with mild gastrointestinal and dermatological adverse events. Although the optimal treatment to this disease remains uncertain, the current approach consisting of systemic anti\u2010angiogenic drugs with or without hypofractionated radiation therapy, provided clinical benefit in a significant proportion of dogs and should, therefore, be further explored.<\/jats:p>","DOI":"10.1111\/vco.12407","type":"journal-article","created":{"date-parts":[[2018,5,28]],"date-time":"2018-05-28T04:39:39Z","timestamp":1527482379000},"page":"497-504","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma"],"prefix":"10.1111","volume":"16","author":[{"given":"F.","family":"Rossi","sequence":"first","affiliation":[{"name":"Centro Oncologico Veterinario  Bologna Italy"},{"name":"Clinica Veterinaria dell'Orologio  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sabattini","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medical Sciences University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vascellari","sequence":"additional","affiliation":[{"name":"Istituto Zooprofilattico Sperimentale delle Venezie  Padova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7843-615X","authenticated-orcid":false,"given":"L.","family":"Marconato","sequence":"additional","affiliation":[{"name":"Centro Oncologico Veterinario  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.2001.219.1110"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.235.8.967"},{"key":"e_1_2_9_4_1","first-page":"4269","article-title":"Cox\u20102 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance","volume":"25","author":"Queiroga FL","year":"2005","journal-title":"Anticancer Res"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq345"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9776(11)70308-3"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2010.04.004"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/vetrec.165.3.78"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.12.039"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12209"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300985813503568"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpa.2009.06.004"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rvsc.2006.01.007"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2011.00883.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300985809353167"},{"key":"e_1_2_9_16_1","volume-title":"Histological Classification of Mammary Tumors of the Dog and the Cat","author":"Misdorp W","year":"1999"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300985812447830"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.103764"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.283"},{"key":"e_1_2_9_20_1","first-page":"157","article-title":"Optimum field size and choice of isodose lines in electron beam treatment","volume":"3","author":"IJ D","year":"1995","journal-title":"Int J Radiot Oncol Biol Phys"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1740-8261.2001.tb00973.x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12032"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12309"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2013.02.009"},{"key":"e_1_2_9_25_1","first-page":"506","article-title":"Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase\u20102 expression, and response to piroxicam treatment","volume":"50","author":"M Souza CH","year":"2009","journal-title":"Can Vet J"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12193"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/vru.12308"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsap.12796"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.173.3.699"},{"key":"e_1_2_9_30_1","first-page":"2481","article-title":"Thalidomide down\u2010regulates the expression of VEGF and bFGF in cisplatin\u2010resistant human lung carcinoma cells","volume":"23","author":"Li X","year":"2003","journal-title":"Anticancer Res"},{"key":"e_1_2_9_31_1","first-page":"632","volume-title":"Cancer Chemotherapy and Biotherapy: Principles and Practice","author":"Laubach J","year":"2011"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3406"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.11.037"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20082"},{"key":"e_1_2_9_35_1","first-page":"2755","article-title":"Phase I dose\u2010escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies","volume":"9","author":"London CA","year":"2003","journal-title":"Clin Cancer Res"}],"container-title":["Veterinary and Comparative Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fvco.12407","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vco.12407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T12:54:56Z","timestamp":1694782496000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vco.12407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,27]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1111\/vco.12407"],"URL":"https:\/\/doi.org\/10.1111\/vco.12407","archive":["Portico"],"relation":{},"ISSN":["1476-5810","1476-5829"],"issn-type":[{"value":"1476-5810","type":"print"},{"value":"1476-5829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,27]]},"assertion":[{"value":"2018-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}